-
A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party
Meral Beksaç, Simona Iacobelli, Linda Köster, Didier Blaise, Jan J. Cornelissen, Peter Pal Remenyi, +19 more
4citations -
Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival - an Analysis By the German Study Group for MPN (GSG-MPN)2024 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Kirsi Marjaana Manz, Florian Heinrich Heidel, Steffen Koschmieder, Rudolf Schlag, Joerg Lipke, Frank Stegelmann, +14 more
3citations -
Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT
Marie Robin, Simona Iacobelli, Jakob Robert Passweg, Linda Köster, Victoria T. Potter, Keith M. O. Wilson, +19 more
3citations -
An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial
Jun‐ichi Nishimura, Antoine Soubret, Simon Buatois, Jean‐Eric Charoin, Sasha Sreckovic, Christoph Marcus Bucher, +21 more
3citations -
COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria
Régis Peffault de Latour, Simona Sica, Julia G. Ramos, Jules Hernández‐Sánchez, Jin Seok Kim, Anna Kiialainen, +11 more
3citations -
Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Steffen Koschmieder, Susanne Isfort, Florian Heinrich Heidel, Andreas Hochhaus, Heiko Becker, Philipp Jakob Jost, +19 more
3citations -
Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status
Heiko Becker, Claudia Schmoor, Olga Grishina, Dietmar Pfeifer, Dennis Zimmer, Martina Margrit Crysandt, +27 more
3citations -
Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1-Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients
Marius Bill, Jan‐Niklas Eckardt, Christian R. Rausch, Klaus Hans Metzeler, Karsten Spiekermann, Sebastian Stasik, +34 more
3citations -
Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials
Ruben A. Mesa, Andrew Charles Perkins, Yeow Tee Goh, María Laura Fox, Donal P. McLornan, Jeanne M. Palmer, +8 more
3citations -
Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
DONATELLA BARONCIANI, Josu de la Fuente, Jacques‐Emmanuel Galimard, Arnaud Dalissier, Ashrafsadat Mousavi, Mehmet Akif Yesilipek, +13 more
3citations -
Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study
Michael W. Schuster, Miguel Ángel Canales, Jason R. Westin, Josée M. Zijlstra, George Follows, Reem Karmali, +32 more
3citations -
Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study
Michael W. Schuster, Miguel Ángel Canales, Jason R. Westin, Josée M. Zijlstra, George Follows, Reem Karmali, +32 more
3citations -
Tub-010, a Novel Antibody-Drug-Conjugate with Reduced Nonspecific Toxicity Profile Based on Tub-Tag Technology Widens the Therapeutic Window for the Treatment of CD30+ Malignancies
Marcus Gerlach, Saskia Schmitt, Philipp Cyprys, Marc‐André Kasper, Isabelle Mai, Maarten H. Vermeer, +5 more
3citations -
Polb 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome (CRS)2023 Blood conference-abstract Immunology and Microbiology Immunotoxicology and immune responses cited by 3 patents
Emma J Searle, Liam Friel Tremble, Rakesh Popat, Digna T. de Bruin, Matthijs Moerland, Brendan Martin Buckley
3citations -
COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
Per T Ljungman, Rafael de la Cámara, Małgorzata Mikulska, Gloria Tridello, Beatriz Aguado, Yves P. Beguin, +31 more
3citations -
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
Larry Don Anderson, Jonathan L. Kaufman, Jacob P. Laubach, Douglas Weston Sborov, Brandi Reeves, Cesar Rodriguez, +21 more
3citations